File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/vaccines8040754
- Scopus: eid_2-s2.0-85097951896
- PMID: 33322574
- WOS: WOS:000601759300001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
Title | Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine |
---|---|
Authors | |
Keywords | influenza vaccine vaccine adjuvant TFH miltefosine |
Issue Date | 2020 |
Publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/vaccines/ |
Citation | Vaccines , 2020, v. 8 n. 4, p. article no. 754 How to Cite? |
Abstract | We previously reported that topical imiquimod can improve the immunogenicity of the influenza vaccine. This study investigated another FDA-approved drug, miltefosine (MTF), as a vaccine adjuvant. Mice immunized with an influenza vaccine with or without MTF adjuvant were challenged by a lethal dose of influenza virus 3 or 7 days after vaccination. Survival, body weight, antibody response, histopathological changes, viral loads, cytokine levels, and T cell frequencies were compared. The MTF-adjuvanted vaccine (MTF-VAC) group had a significantly better survival rate than the vaccine-only (VAC) group, when administered 3 days (80% vs. 26.7%, p = 0.0063) or 7 days (96% vs. 65%, p = 0.0041) before influenza virus challenge. Lung damage was significantly ameliorated in the MTF-VAC group. Antibody response was significantly augmented in the MTF-VAC group against both homologous and heterologous influenza strains. There was a greater T follicular helper cell (TFH) response and an enhanced germinal center (GC) reaction in the MTF-VAC group. MTF-VAC also induced both TH1 and TH2 antigen-specific cytokine responses. MTF improved the efficacy of the influenza vaccine against homologous and heterologous viruses by improving the TFH and antibody responses. Miltefosine may also be used for other vaccines, including the upcoming vaccines for COVID-19. |
Persistent Identifier | http://hdl.handle.net/10722/304981 |
ISSN | 2023 Impact Factor: 5.2 2023 SCImago Journal Rankings: 1.201 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lu, L | - |
dc.contributor.author | Fong, CHY | - |
dc.contributor.author | Zhang, AJ | - |
dc.contributor.author | Wu, WL | - |
dc.contributor.author | Li, IC | - |
dc.contributor.author | Lee, ACY | - |
dc.contributor.author | Dissanayake, TK | - |
dc.contributor.author | Chen, L | - |
dc.contributor.author | Hung, IFN | - |
dc.contributor.author | Chan, KH | - |
dc.contributor.author | Chu, H | - |
dc.contributor.author | Kok, KH | - |
dc.contributor.author | Yuen, KY | - |
dc.contributor.author | To, KKW | - |
dc.date.accessioned | 2021-10-05T02:38:01Z | - |
dc.date.available | 2021-10-05T02:38:01Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Vaccines , 2020, v. 8 n. 4, p. article no. 754 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | http://hdl.handle.net/10722/304981 | - |
dc.description.abstract | We previously reported that topical imiquimod can improve the immunogenicity of the influenza vaccine. This study investigated another FDA-approved drug, miltefosine (MTF), as a vaccine adjuvant. Mice immunized with an influenza vaccine with or without MTF adjuvant were challenged by a lethal dose of influenza virus 3 or 7 days after vaccination. Survival, body weight, antibody response, histopathological changes, viral loads, cytokine levels, and T cell frequencies were compared. The MTF-adjuvanted vaccine (MTF-VAC) group had a significantly better survival rate than the vaccine-only (VAC) group, when administered 3 days (80% vs. 26.7%, p = 0.0063) or 7 days (96% vs. 65%, p = 0.0041) before influenza virus challenge. Lung damage was significantly ameliorated in the MTF-VAC group. Antibody response was significantly augmented in the MTF-VAC group against both homologous and heterologous influenza strains. There was a greater T follicular helper cell (TFH) response and an enhanced germinal center (GC) reaction in the MTF-VAC group. MTF-VAC also induced both TH1 and TH2 antigen-specific cytokine responses. MTF improved the efficacy of the influenza vaccine against homologous and heterologous viruses by improving the TFH and antibody responses. Miltefosine may also be used for other vaccines, including the upcoming vaccines for COVID-19. | - |
dc.language | eng | - |
dc.publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/vaccines/ | - |
dc.relation.ispartof | Vaccines | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | influenza vaccine | - |
dc.subject | vaccine | - |
dc.subject | adjuvant | - |
dc.subject | TFH | - |
dc.subject | miltefosine | - |
dc.title | Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine | - |
dc.type | Article | - |
dc.identifier.email | Lu, L: ilulu@hku.hk | - |
dc.identifier.email | Fong, CHY: chyfong@hku.hk | - |
dc.identifier.email | Zhang, AJ: zhangajx@hkucc.hku.hk | - |
dc.identifier.email | Wu, WL: hazelwu@hkucc.hku.hk | - |
dc.identifier.email | Li, IC: canlee@hku.hk | - |
dc.identifier.email | Lee, ACY: cyalee@hku.hk | - |
dc.identifier.email | Hung, IFN: ivanhung@hkucc.hku.hk | - |
dc.identifier.email | Chan, KH: chankh2@hkucc.hku.hk | - |
dc.identifier.email | Chu, H: hinchu@hku.hk | - |
dc.identifier.email | Kok, KH: khkok@hku.hk | - |
dc.identifier.email | Yuen, KY: kyyuen@hkucc.hku.hk | - |
dc.identifier.email | To, KKW: kelvinto@hku.hk | - |
dc.identifier.authority | Zhang, AJ=rp00413 | - |
dc.identifier.authority | Hung, IFN=rp00508 | - |
dc.identifier.authority | Chan, KH=rp01921 | - |
dc.identifier.authority | Chu, H=rp02125 | - |
dc.identifier.authority | Kok, KH=rp01455 | - |
dc.identifier.authority | Yuen, KY=rp00366 | - |
dc.identifier.authority | To, KKW=rp01384 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3390/vaccines8040754 | - |
dc.identifier.pmid | 33322574 | - |
dc.identifier.pmcid | PMC7768360 | - |
dc.identifier.scopus | eid_2-s2.0-85097951896 | - |
dc.identifier.hkuros | 326105 | - |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | article no. 754 | - |
dc.identifier.epage | article no. 754 | - |
dc.identifier.isi | WOS:000601759300001 | - |
dc.publisher.place | Switzerland | - |